Molecular Genetics and Genomics (MGG) Specialty Training Framework
American College of Medical Genetics and Genomics (ACMG)
Alternative Pathway to Board Certification in
Laboratory Genetics and Genomics
Planning Committee (March 2019)
Thomas William Prior, PhD, FACMG (Chair of Molecular Genetics and Genomics Pathway)
Professor of Pathology and Director of the Molecular Genetics Laboratory at Case Western Reserve University
Nicole Hoppman, PhD, FACMG (Chair of Cytogenetics and Genomics Pathway)
Co-director of the Genomics Laboratory (combined clinical cytogenetics and molecular genetics) at Mayo Clinic
Program Director of the Laboratory Genetics and Genomics Fellowship
Azra Ligon, PhD, FACMG
Chair, American Board of Medical Genetics and Genomics Board of Directors
Associate Professor of Pathology at Harvard Medical School
Chief of Clinical Cytogenetics at Brigham and Women’s Hospital
Swaroop Aradhya, PhD, FACMG
Head of Global Medical Affairs at Invitae
Katie Rudd, PhD, FACMG
Cytogenetics Director at Laboratory Corporation of America Holdings
Elaine Lyon, PhD, FACMG
Director, Clinical Services Laboratory, LLC
HudsonAlpha Institute for Biotechnology
Catherine Rehder, PhD, FACMG
Associate Professor, Department of Pathology
Director, Clinical Cytogenetics Laboratory
Associate Director, Molecular Diagnostics Laboratory
Duke University Health System Clinical Laboratories
Julie M. Gastier-Foster, PhD, FACMG
Senior Director, Institute for Genomic Medicine Clinical Laboratory
Vice Chair, Pathology and Laboratory Medicine
PI, COG and SWOG Leukemia Banks and COG Reference Laboratories
PI, Biospecimen Core Resource
Nationwide Children's Hospital
Professor Clinical, Departments of Pathology and Pediatrics, The Ohio State University College of Medicine
Cindy L. Vnencak-Jones, PhD, FACMG
Professor, Departments of Pathology, Microbiology & Immunology and Pediatrics
Medical Director, Molecular Diagnostics Lab
Vanderbilt University Medical Center
Gerald (Jerry) Feldman, MD, PhD, FACMG
Professor, Molecular Medicine and Genetics, Pediatrics and Pathology
Director, Clinical Genetic Services, Wayne State University School of Medicine
Director, Division of Laboratory Genetics and Molecular Pathology, Detroit Medical Center University Laboratories
ACMG Staff:
Mike Watson, PhD, FACMG
Executive Director
Jane Radford, MHA, CHCP
Associate Director of Education
Contributor:
Miriam (Mimi) Blitzer, PhD, FACMG
Chief Executive Officer, American Board of Medical Genetics and Genomics
Financial Disclosures
It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, platform presenters, presenting authors, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.
This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity.
ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.
NOTE:
- ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.
- The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
- The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
- Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.
The following have reported disclosures:
Julie Gastier-Foster, PhD, FACMG
Dr. Gastier-Foster receives grant support from NCI Cancer Genomics, Bristol Myers Squibb and Incyte Corporation.
Elaine Lyon, PhD, FACMG
Dr. Lyon is a consultant for Genoox and is on the Board of Directors for the American College of Medical Genetics and Genomics.
Catherine Rehder, PhD, FACMG
Dr. Rehder receives grant support from NICHD. She is a consultant with Illumina and her spouse is a consultant with McKesson. She is a member of the Board of Directors for the American College of Medical Genetics and Genomics and the American Cytogenomics Conference.
Katie Rudd, PhD, FACMG
Dr. Rudd is employed with Laboratory Corporation of America Holdings. Participation in planning and writing case study questions are not in line with any clinical applications or recommendations, business lines or products of her employer.
The following planning members, staff and contributors have nothing to disclose:
Azra Ligon, PhD, FACMG
Gerald (Jerry) Feldman, MD, PhD, FACMG
Cindy Vnencak-Jones, PhD, FACMG
Thomas William Prior, PhD, FACMG
Swaroop Aradhya, PhD, FACMG
Nicole Hoppman, PhD, FACMG
ACMG Staff:
Mike Watson, PhD, FACMG
Jane Radford, MHA, CHCP
Contributor:
Miriam (Mimi) Blitzer, PhD, FACMG